Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CFZ533 in moderately active proliferative lupus nephritis
2017-003230-93Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in lupus nephritis (LN) comparing CFZ533 + standard of care with Placebo + standard of care (2 arms). Primary endpoints: Safety and tolerability over 24 weeks and Pharmacokinetics of CFZ533. Started Mar 2018; status: completed.
02
Drugs
iscalimab
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on 2017-003230-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003230-93.